Loading patent…
AssigneeBoard of Regents, The University of Texas System
InventorTheresa M. Siler-Khodr
Estimating the term…
Methods for inhibiting the production of specific vasoconstrictive prostanoids, such as thromboxane and prostaglandin F2α, through the addition of insulin like growth factor, particularly IGF-I or IGF-II, to human placental cells are disclosed. IGF-I is demonstrated to avoid affecting material and placental production of prostaglandin E, human chorionic gonadotropin, PGFM, and 6-keto-PGF1-alpha by placental cells. Improved methods for vasoregulation of vasoconstrictive diseases of pregnancy are also disclosed. Methods for treating hypertension with IGF-I are also described. Improved methods for inhibiting pre-term labor are also provided. Methods for inducing labor with agents that specifically inhibit insulin like growth factor are also disclosed. Such inhibitors of IGF-I include antibodies, antagonists of IGF-I, and metabolizing enzymes of IGF-I.
A method for regulating placental cell production of thromboxane and PGF2α comprising treating placental cells with a pharmacologically effective amount of insulin-like growth factor I sufficient to inhibit thromboxane and prostaglandin F2α production without affecting prostacyclin or prostaglandin E2 production.
A method for inhibiting labor by inhibiting the production of prostaglandin F2α and thromboxane by chorionic tissue comprising administering to a pregnant animal a pharmacologically effective amount of insulin like growth factor I or an analog thereof sufficient to inhibit the production of thromboxane and prostaglandin F2α by placental cells without affecting prostacyclin, PGE, PGFM and human chorionic gonadotropin production.
Dependencies are inferred from the claim text.